Serving more than 3,000 patients each day, Miraca Life Sciences is a leader in providing an academic-caliber clinical pathology laboratory with diagnostic services in the fields of dermatology, gastroenterology, hematology and urology. Building upon our experience with health IT, we also offer accessible EHR solutions to assist healthcare professionals as they work towards accordance with Meaningful Use initiatives.
We employ a talented team of leading pathologists, histologists, lab technicians, technology consultants, and other medical professionals — all driven to help provide the highest and most up-to-date levels of diagnostic quality, enhanced workflow and practice solutions possible. It’s part of our commitment: not only to scientific excellence, but to you.
Our skilled team of field-specific clinical pathologists, consultants and experts work diligently to stay at the forefront of the ever-changing landscape of a pathology laboratory and health IT. As part of this diligence, we work closely with one another to provide the highest quality, academic-based research and information possible.
Digestive Diseases Week (DDW) 2013: Seven Miraca Life Sciences Abstracts Accepted As in previous years, Miraca Life Scie …»
European studies have shown that long-term proton-pump inhibitor (PPI) therapy in patients with GERD and antrum-predomin …»
Mutation and/or deletion of p53, a cell cycle regulatory gene, is a promising biomarker for predicting the risk of neopl …»
It is unknown whether the subtypes of microscopic colitis represent distinct nosologic entities or related presentations …»
February 21, 2013
The American Society for Gastrointestinal Endoscopy (ASGE) Foundation has received a donation of $100,000 from Miraca Life Sciences to ASGE's IT&T Capital Campaign, a fundraising project to construct a new facility that will provide cutting-edge technology and training capabilities to significantly optimize current educational opportunities. The donation will be made over five years.
Continue reading
January 15, 2013
Irving, Texas, January 15, 2013 – Miraca Life Sciences is excited to announce the initiation of a new testing protocol that will aid in the management of patients with gastroesophageal adenocarcinoma. This protocol is in response to the 2010 "ToGA" (Trastuzumab in Gastric cancer) clinical trial that demonstrated a clear survival benefit for combining …
Continue reading